European Commission Approves Parsabiv ™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

First Treatment Advance for Secondary Hyperparathyroidism in More Than a Decade and First Intravenous Calcimimetic to Help Healthcare Providers Lower Key Lab Values THOUSAND OAKS, Calif., Nov. 11, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a hemodialysis session. "Keeping relevant lab values in recommended targe...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news